Prognostic Value of N-Terminal Pro-Brain Natriuretic Peptide and High-Sensitivity Troponin T Levels in the Natural History of Transthyretin Amyloid Cardiomyopathy and Their Evolution after Tafamidis Treatment.
biomarkers
cardiac amyloidosis
heart failure
prognosis
tafamidis
transthyretin
treatment
Journal
Journal of clinical medicine
ISSN: 2077-0383
Titre abrégé: J Clin Med
Pays: Switzerland
ID NLM: 101606588
Informations de publication
Date de publication:
22 Oct 2021
22 Oct 2021
Historique:
received:
19
09
2021
revised:
06
10
2021
accepted:
14
10
2021
entrez:
13
11
2021
pubmed:
14
11
2021
medline:
14
11
2021
Statut:
epublish
Résumé
We assesse the evolution and prognostic value of N-terminal pro-brain natriuretic peptide (NT-proBNP) and high-sensitivity troponin T (cTnT-HS) in transthyretin amyloid cardiomyopathy (ATTR-CA) before and after tafamidis treatment. 454 ATTR-CA patients without tafamidis (Cohort A) and 248 ATTR-CA with tafamidis (Cohort B) were enrolled. Event-free survival (EFS) events were death, heart transplant, or acute heart failure. In Cohort A, 27% of patients maintained NT-proBNP < 3000 ng/L and 14% cTnT-HS < 50 ng/L at 12 months relative to baseline levels. In Cohort B, the proportions were 49% and 29%, respectively. In Cohort A, among the 333 patients without an increased NT-proBNP > 50% relative to baseline EFS was extended compared to the 121 patients with an increased NT-proBNP > 50% (HR: 0.75 [0.57; 0.98]; ATTR-CA patients with increasing NT-proBNP had an increased risk of EFS. Tafamidis stabilize NT-proBNP and cTnT-HS increasing, even if initial NT-proBNP levels were >3000 ng/L. Thus suggesting that all patients, irrespective of baseline NT-proBNP levels, may benefit from tafamidis.
Sections du résumé
BACKGROUND
BACKGROUND
We assesse the evolution and prognostic value of N-terminal pro-brain natriuretic peptide (NT-proBNP) and high-sensitivity troponin T (cTnT-HS) in transthyretin amyloid cardiomyopathy (ATTR-CA) before and after tafamidis treatment.
METHODS AND RESULTS
RESULTS
454 ATTR-CA patients without tafamidis (Cohort A) and 248 ATTR-CA with tafamidis (Cohort B) were enrolled. Event-free survival (EFS) events were death, heart transplant, or acute heart failure. In Cohort A, 27% of patients maintained NT-proBNP < 3000 ng/L and 14% cTnT-HS < 50 ng/L at 12 months relative to baseline levels. In Cohort B, the proportions were 49% and 29%, respectively. In Cohort A, among the 333 patients without an increased NT-proBNP > 50% relative to baseline EFS was extended compared to the 121 patients with an increased NT-proBNP > 50% (HR: 0.75 [0.57; 0.98];
CONCLUSION
CONCLUSIONS
ATTR-CA patients with increasing NT-proBNP had an increased risk of EFS. Tafamidis stabilize NT-proBNP and cTnT-HS increasing, even if initial NT-proBNP levels were >3000 ng/L. Thus suggesting that all patients, irrespective of baseline NT-proBNP levels, may benefit from tafamidis.
Identifiants
pubmed: 34768388
pii: jcm10214868
doi: 10.3390/jcm10214868
pmc: PMC8584290
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : AREMCAR
ID : 0
Références
J Cardiol. 2016 Aug;68(2):110-6
pubmed: 26775889
JACC Basic Transl Sci. 2018 Dec 31;3(6):871-873
pubmed: 30623146
Clin Res Cardiol. 2020 Jun;109(6):700-713
pubmed: 31630214
BMJ Open. 2019 Apr 20;9(4):e026030
pubmed: 31005928
Int J Epidemiol. 2001 Dec;30(6):1332-41
pubmed: 11821342
Heart. 2014 Mar;100(5):383-8
pubmed: 24402772
Clin Cardiol. 2009 Nov;32(11):E39-42
pubmed: 19816977
J Geriatr Cardiol. 2014 Jun;11(2):136-40
pubmed: 25009564
N Engl J Med. 2018 Sep 13;379(11):1007-1016
pubmed: 30145929
J Am Coll Cardiol. 2000 Sep;36(3):959-69
pubmed: 10987628
Neurol Ther. 2016 Jun;5(1):1-25
pubmed: 26894299
J Am Coll Cardiol. 2016 Sep 6;68(10):1014-20
pubmed: 27585505
Amyloid. 2013 Dec;20(4):212-20
pubmed: 23964755
Leukemia. 2012 Nov;26(11):2317-25
pubmed: 22475872
Blood. 2019 Feb 14;133(7):763-766
pubmed: 30545829
ESC Heart Fail. 2020 Sep 13;:
pubmed: 32924285
J Am Heart Assoc. 2014 Jan 27;3(1):e000403
pubmed: 24470520
Circulation. 2003 May 20;107(19):2440-5
pubmed: 12719281
Circulation. 2019 Jan 22;139(4):444-447
pubmed: 30664380
Int J Mol Sci. 2019 Apr 12;20(8):
pubmed: 31013779
J Cardiol. 2020 Jan;75(1):12-19
pubmed: 31324572
Haematologica. 2014 Feb;99(2):209-21
pubmed: 24497558
Blood. 2010 Nov 4;116(18):3426-30
pubmed: 20644111
Eur J Heart Fail. 2004 Mar 15;6(3):257-60
pubmed: 14987573
Eur J Heart Fail. 2021 Feb;23(2):217-230
pubmed: 33527656
Amyloid. 2016 Sep;23(3):194-202
pubmed: 27647161
Eur Heart J. 2018 Aug 7;39(30):2799-2806
pubmed: 29048471
Clin Lab Sci. 2006 Fall;19(4):214-7
pubmed: 17181125